Status:
COMPLETED
Vildagliptin and the Glucagon Response to Hypoglycemia in Insulin-Treated Patients With Type 2 Diabetes
Lead Sponsor:
Lund University
Conditions:
Diabetes
Eligibility:
All Genders
18-75 years
Phase:
PHASE4
Brief Summary
The purpose of this study is to explore whether the novel therapy of type 2 diabetes, vildagliptin, which inhibits dipeptidyl peptidase-4 (DPP-4), affects glucagon counterregulation during hypoglycemi...
Detailed Description
Vildagliptin is an inhibitor of dipeptidyl peptidase-4 (DPP-4) and inhibits glucagon secretion and stimulates insulin secretion. This improves glycemia in subjects with type 2 diabetes with a very low...
Eligibility Criteria
Inclusion
- Type 2 diabetes
- Insulin treatment
- Age \>18 years
- HbA1c \<=8.5%
Exclusion
- Pregnancy
- Lactation
- Acute infection
- Liver disease
- Treatment with cortisol
Key Trial Info
Start Date :
January 1 2012
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2013
Estimated Enrollment :
28 Patients enrolled
Trial Details
Trial ID
NCT01219400
Start Date
January 1 2012
End Date
December 1 2013
Last Update
September 30 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Lund University
Lund, Sweden, 22184